SWEDISH ENGLISH CONTACT US BioInvent About BioInvent Projects Partners Science Investors Media Centre BioInvent is a research-based pharmaceutical company focused on the discovery and development of innovative antibody-based drugs against cancer. OUR PIPELINE BioInvent has three proprietary antibodies in or close to clinical development to fight various cancers. BI-505 – multiple myeloma BI-1206 – non-Hodgkin-lymphoma TB-403 – medulloblastoma In addition, BioInvent has a number of research stage projects that we consider promising; especially in the field of immuno-oncology. READ MORE F.I.R.S.T.™ Enables combined target and drug discovery No prior knowledge of the target is required Allows for direct functional screening Identifies disease targets that: have a higher level of protein expression without a corresponding increase in mRNA expression include post-translational modifications are generated through protein-protein interactions READ MORE PRESS RELEASES MEET US 7-11 Oct, 2016, ESMO, Copenhagen, Denmark 2.77SEK BID 2.74 ASK 2.77 HIGH 2.8 LOW 2.7 VOLUME 182,206 TURNOVER 497,191.64 UPDATED 2015-09-01 18:00 CONTACT US LEGAL DISCLAIMER Copyright © BioInvent International AB